Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab-Reference-Cited by-同舟云学术

Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

Published:2022-03-24 Issue:6 Volume:91 Page:796-800
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Annals of Neurology

Author:

Brill Livnat¹^ORCID,Raposo Catarina²,Rechtman Ariel¹,Zveik Omri¹^ORCID,Levin Netta¹^ORCID,Oiknine‐Djian Esther³⁴,Wolf Dana G.³⁴,Vaknin‐Dembinsky Adi¹

Affiliation:

1. Department of Neurology, Laboratory of Neuroimmunology, and Agnes‐Ginges Center for Neurogenetics Hadassah‐Hebrew University Medical Center Jerusalem Israel

2. F. Hoffmann‐La Roche Basel Switzerland

3. Clinical Virology Unit Hadassah Hebrew University Medical Center Jerusalem Israel

4. Lautenberg Center for General and Tumor Immunology Hebrew University Faculty of Medicine Jerusalem Israel

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.26343

Reference20 articles.

1. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

2. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

3. Impact of multiple sclerosis disease‐modifying therapies on SARS‐CoV‐2 vaccine‐induced antibody and T cell immunity;Sabatino JJ;medRxiv,2021

4. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

5. Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants;Science Bulletin;2024-08

2. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination;Annals of Clinical and Translational Neurology;2024-05-07

3. Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination;2024-01-24

4. COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022;Multiple Sclerosis Journal;2024-01-21

5. Multiple sclerosis;The Lancet;2024-01